IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

09 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

06 Nov 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

03 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

Immutep to Participate in November Investor Events

02 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report Q1 FY24

31 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep receives ~A$1.13 million R&D Tax Incentive

25 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

24 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

23 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Publication of Abstracts at ESMO Congress 2023

16 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

03 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

21 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep to Participate in September Investor Conferences

05 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Immutep Receives Positive Scientific Advice from European Medicines Agency

01 Aug 2023 08:00:02 By Nasdaq GlobeNewswire

Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023

31 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report Q4 FY23

31 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

28 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor

27 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Completes A$80 Million Capital Raise

27 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3

20 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep to Participate at the Jefferies Healthcare Conference

07 Jun 2023 08:00:00 By Nasdaq GlobeNewswire